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Transgenic plants are promising alternatives for the pro-
duction of recombinant pharmaceutical proteins (plant
molecular farming). Plants as higher eukaryotes perform
posttranslational modifications similar to those of mam-
malian cell lines. Low-cost cultivation and safe pathogen-
free production are further advantages. However, field cul-
tivation of transgenic plants raises social, environmental
and regulatory challenges that need to be addressed when
considering how plant-made pharmaceuticals might be
successfully commercialized. Especially GMP conditions
are hard to achieve for the field production of pharmaceu-
ticals. Moreover, plant-specific protein N-glycosylation
was shown to be immunogenic, a fact that represents a
drawback for many plant systems as biofactories for a
broad spectrum of biopharmaceuticals. The moss Phys-
comitrella patens offers unique properties as a safe con-
tained system for protein production [1]. It is grown in the
dominant haploid gametophytic stage as tissue suspen-
sion cultures in photobioreactors. Photo-autotrophic
growth enables cultivation in a simple and cheap mineral
medium. The generation of stable transgenic lines is easy
and a relatively short-term procedure. The moss is geneti-
cally well characterized and displays no special codon
usage preferences allowing the high-level expression of
human cDNAs without prior codon optimization. Strong
promoters for foreign gene expression have been charac-
terized from both, heterologous as well as endogenous
genes. Efficient secretory signals and a transient transfec-
tion system allow the secretion of freshly synthesized pro-
teins to the surrounding medium. The secretory system
offers continuous harvesting of the product without the
necessity to lyse the producing cells and eased down-
stream isolation and purification steps. The key advantage
of Physcomitrella compared to other plant systems is its
high degree of nuclear homologous recombination ena-
bling targeted gene replacements. By this means, plant-
specific glycosyltransferase genes, i.e. beta1,2-xylosyl-
transferase and alpha1,3-fucosyltransferase were specifi-
cally knocked out and human-type beta1,4-
galactosyltransferase was introduced. The resultant moss
strains provide proteins with non-immunogenic human-
ized glycan patterns.
Here we present an overview of the relevant aspects for
establishing moss as a production system for recombinant
biopharmaceuticals.
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